IL-17 Receptor inhibition with brodalumab limits experimental periodontitis.

Brodalumab, an IL-17 receptor inhibitor, reduced inflammatory responses and alveolar bone loss in mice with experimentally induced periodontitis, with effects increasing at higher doses and approaching healthy levels by day 8.

A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.